Endocyte shares up 50% as part of a $ 2.1 billion deal with Novartis

Endocyte shares rose about 50% in pre-market trading after Swiss drug maker Novartis agreed to buy US-based biopharmaceutical company for $ 2.1 billion of dollars.

Source link